BusinessRhizen Pharmaceuticals S.A. receives FDA Fast Track Designation for Tenalisib (RP6530), a highly selective dual PI3K delta/gamma inhibitor for the treatment of patients with relapsed and/or refractory Cutaneous T-cell Lymphoma (CTCL)By Nasdaq OMXApr 13, 2018, 11:00 AM UTC
BusinessRhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual MeetingBy Nasdaq OMXApr 10, 2018, 11:00 AM UTC
BusinessRhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USABy Nasdaq OMXOct 24, 2017, 11:00 AM UTC
